Study wrapper · #518
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
Editor's note
This is a post hoc analysis of a phase III double-blind, placebo-controlled trial asking whether the presence of dorsocervical fat (a 'buffalo hump') affects tesamorelin's efficacy in reducing visceral fat in people with HIV. Among tesamorelin responders, researchers reported that visceral adipose tissue and waist circumference decreased similarly whether or not dorsocervical fat was present, with no statistically significant difference between groups. As a post hoc, subgroup analysis it is hypothesis-refining rather than confirmatory, and it examines responders specifically. Still, it draws on robust phase III data and supports a practical clinical point: tesamorelin's visceral-fat effect appears consistent regardless of dorsocervical fat status, aligning with the drug's established indication.
Plain-language abstract
Some people with HIV develop a fat pad at the back of the neck and upper shoulders (sometimes called a 'buffalo hump'). Researchers reanalyzed data from a large, high-quality trial to ask whether having this neck fat changed how well tesamorelin — a growth-hormone-releasing hormone analog — reduced deep belly fat. Looking at people who responded to the drug, they found that deep belly fat and waist size dropped by similar amounts whether or not the person had the neck fat pad; the differences were not statistically meaningful. The authors conclude that tesamorelin appears equally useful for reducing excess deep abdominal fat regardless of neck-fat status. Because this was an after-the-fact analysis of a subgroup, it refines rather than proves the point, but it rests on data from a rigorous trial.